{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(1)"],"submitter":["Chen BS"],"pubmed_abstract":["<h4>Objectives</h4>This study aimed to evaluate the suitability of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) for measuring vision-related quality of life (VRQoL) in patients with Leber hereditary optic neuropathy receiving lenadogene nolparvovec gene therapy in three Phase III randomised controlled clinical trials.<h4>Methods</h4>VRQoL was assessed using the NEI-VFQ-25 at baseline (n=174) and 2 years after treatment (n=152). All participants received lenadogene nolparvovec in at least one eye. The scoring structure of the original NEI-VFQ-25 was evaluated for fit to the Rasch model, and a post hoc revision was created and psychometrically reevaluated. Stacked analysis was conducted to compare Rasch-revised scores at baseline and 2 years after treatment.<h4>Resul"],"journal":["BMJ open ophthalmology"],"pagination":["e002164"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12458720"],"repository":["biostudies-literature"],"pubmed_title":["Rasch analysis of the NEI-VFQ-25: vision-related quality of life in Leber hereditary optic neuropathy after lenadogene nolparvovec gene therapy."],"pmcid":["PMC12458720"],"pubmed_authors":["Wilkins S","Acheson J","Mathias M","Hubbard GB","Sergott RC","Haller JA","Calcagno F","Thornton S","Patel S","DeBusk AA","Hendrick AM","Neuenhahn M","Preston M","Hwang JM","Schertler C","LHON Study Group","Silvestri S","Horton M","Romagnoli M","Memon MA","Tsui I","DuBois L","Wang AG","Castillo L","Carbonelli M","Priglinger C","Rudolph G","Hawy E","Hage R","Gibbs D","Cheng HC","Vito LD","Khemliche W","Cestari D","Priglinger S","Leitch-Devlin L","Boston H","Aung A","Leroy BP","Eleftheriadou M","Banik R","Burale A","Plaine L","Esposti S","Pecen P","Tai K","Yu-Wai-Man P","Jorany R","Muth D","Contin M","Carelli V","Moster ML","Girmens JF","Ruark S","Amore G","Sheel P","Donahue S","Zaeytijd J","Jurkute N","Sun C","Tollis H","Biousse V","Catarino CB","Battista M","Verhauwen H","Fernandez GR","Hussain R","Munoz Negrete FJ","Perot S","Leruez S","Livonius BV","Sadun AA","Taiel M","Thurau S","Gemenetzi M","Sahel JA","Vignal-Clermont C","Dattilo M","Garcia V","Anand S","Barboni P","Chen C","Filho AF","Gangaputra S","Heilweil G","Bandello F","Chen BS","Hildebrandt M","Pressler A","D'Agati P","Klopstock T","Morgia C","Tucker WR","Cascavilla ML","Peragallo JH","Mohamed S","Cauwenbergh CV","Pina A","SantaMaria M","Wolf A","Al-Tamami J","Barrett M","Foroozan R","Karanjia R","Cho S","O'Keefe G","Morilla A","Subramanian PS","Massini M","Dobbs J","Fortin E","Chwalisz BK","Newman NJ","Urquijo LJ"],"additional_accession":[]},"is_claimable":false,"name":"Rasch analysis of the NEI-VFQ-25: vision-related quality of life in Leber hereditary optic neuropathy after lenadogene nolparvovec gene therapy.","description":"<h4>Objectives</h4>This study aimed to evaluate the suitability of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) for measuring vision-related quality of life (VRQoL) in patients with Leber hereditary optic neuropathy receiving lenadogene nolparvovec gene therapy in three Phase III randomised controlled clinical trials.<h4>Methods</h4>VRQoL was assessed using the NEI-VFQ-25 at baseline (n=174) and 2 years after treatment (n=152). All participants received lenadogene nolparvovec in at least one eye. The scoring structure of the original NEI-VFQ-25 was evaluated for fit to the Rasch model, and a post hoc revision was created and psychometrically reevaluated. Stacked analysis was conducted to compare Rasch-revised scores at baseline and 2 years after treatment.<h4>Resul","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-15T06:51:37.276Z","creation":"2026-06-30T03:27:24.821Z"},"accession":"S-EPMC12458720","cross_references":{"pubmed":["40967677"],"doi":["10.1136/bmjophth-2025-002164"]}}